Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast
He predicted the 2020 crash a month before it happened…He predicted this year’s collapse back in January…

And now, he’s issuing a brand-new warning – along with a unique solution.
Details here.

BCDA Insider Trading

Insider Ownership Percentage: 23.30%
Insider Buying (Last 12 Months): $52,913.24
Insider Selling (Last 12 Months): $0.00

BioCardia Insider Trading History Chart

This chart shows the insider buying and selling history at BioCardia by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioCardia Share Price & Price History

Current Price: $2.02
Price Change: Price Increase of +0.04 (2.02%)
As of 09/27/2022 01:00 AM ET

This chart shows the closing price history over time for BCDA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

BioCardia Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/23/2022Peter AltmanCEOBuy1,400$1.87$2,618.00328,447View SEC Filing Icon  
9/21/2022Peter AltmanCEOBuy2,750$1.92$5,280.00323,947View SEC Filing Icon  
6/10/2022Peter AltmanCEOBuy4,500$1.46$6,570.00321,197View SEC Filing Icon  
5/13/2022Peter AltmanCEOBuy2,698$1.38$3,723.24348,143View SEC Filing Icon  
5/11/2022Peter AltmanCEOBuy1,000$1.30$1,300.00334,143View SEC Filing Icon  
4/28/2022Peter AltmanCEOBuy2,300$1.59$3,657.00330,443View SEC Filing Icon  
4/18/2022Peter AltmanCEOBuy13,500$1.39$18,765.00328,143View SEC Filing Icon  
11/18/2021Peter AltmanCEOBuy5,000$2.20$11,000.00View SEC Filing Icon  
8/17/2021Peter AltmanCEOBuy3,500$2.94$10,290.00232,909View SEC Filing Icon  
12/1/2020Peter AltmanCEOBuy1,000$2.49$2,490.00203,200View SEC Filing Icon  
11/27/2020Peter AltmanCEOBuy3,200$2.37$7,584.00203,200View SEC Filing Icon  
11/12/2020Peter AltmanCEOBuy2,000$2.07$4,140.00205,900View SEC Filing Icon  
11/10/2020Peter AltmanCEOBuy2,500$1.98$4,950.00203,900View SEC Filing Icon  
11/2/2020Eric DuckersInsiderSell8,435$2.01$16,954.3512,088View SEC Filing Icon  
6/19/2020Jim L AllenDirectorBuy142,850$2.10$299,985.00668,200View SEC Filing Icon  
3/24/2020Peter AltmanCEOBuy1,200$2.90$3,480.00171,911View SEC Filing Icon  
3/19/2020Peter AltmanCEOBuy400$2.95$1,180.00170,711View SEC Filing Icon  
3/12/2020Peter AltmanCEOBuy3,400$3.15$10,710.00166,811View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for BioCardia (NASDAQ:BCDA)

12.04% of BioCardia stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at BCDA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

BioCardia Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/15/2022Millennium Management LLC28,312$42K0.0%N/A0.162%Search for SEC Filing on Google Icon
5/13/2022Renaissance Technologies LLC13,700$28K0.0%N/A0.081%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.650,523$1.35M0.0%+57.9%3.856%Search for SEC Filing on Google Icon
5/13/2022Dimensional Fund Advisors LP27,407$57K0.0%N/A0.162%Search for SEC Filing on Google Icon
5/4/2022Commonwealth Equity Services LLC49,978$0.10M0.0%+18.1%0.296%Search for SEC Filing on Google Icon
1/31/2022Commonwealth Equity Services LLC42,307$82K0.0%+156.5%0.251%Search for SEC Filing on Google Icon
11/5/2021Advisor Group Holdings Inc.39,257$0.12M0.0%-8.4%0.233%Search for SEC Filing on Google Icon
10/29/2021Commonwealth Equity Services LLC16,492$51K0.0%N/A0.098%Search for SEC Filing on Google Icon
9/17/2021Virtu Financial LLC33,264$0.13M0.0%N/A0.197%Search for SEC Filing on Google Icon
8/25/2021Marshall Wace LLP21,680$86K0.0%-45.7%0.129%Search for SEC Filing on Google Icon
8/16/2021Marshall Wace LLP21,680$86K0.0%-45.7%0.129%Search for SEC Filing on Google Icon
8/13/2021Renaissance Technologies LLC102,230$0.41M0.0%-66.5%0.609%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC76,825$0.30M0.0%+23.6%0.457%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.411,969$1.64M0.0%+67.8%2.453%Search for SEC Filing on Google Icon
8/10/2021CM Management LLC329,000$1.31M0.9%+5.1%1.959%Search for SEC Filing on Google Icon
8/6/2021Magnus Financial Group LLC15,000$60K0.0%N/A0.089%Search for SEC Filing on Google Icon
5/19/2021Squarepoint Ops LLC46,945$0.20M0.0%N/A0.280%Search for SEC Filing on Google Icon
5/13/2021Renaissance Technologies LLC305,200$1.33M0.0%N/A1.817%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC62,168$0.27M0.0%+175.6%0.370%Search for SEC Filing on Google Icon
5/12/2021CM Management LLC313,100$1.36M1.0%+36.1%1.864%Search for SEC Filing on Google Icon
2/9/2021Bank of New York Mellon Corp16,294$56K0.0%N/A0.131%Search for SEC Filing on Google Icon
2/5/2021CM Management LLC230,000$0.80M0.7%N/A1.851%Search for SEC Filing on Google Icon
8/17/2020Jane Street Group LLC14,688$35K0.0%N/A0.214%Search for SEC Filing on Google Icon
8/14/2020Captrust Financial Advisors659,179$1.62M0.0%N/A9.626%Search for SEC Filing on Google Icon
8/14/2020Advisor Group Holdings Inc.85,002$0.20M0.0%-7.7%1.241%Search for SEC Filing on Google Icon
5/18/2020Advisor Group Holdings Inc.92,083$0.31M0.0%N/A1.349%Search for SEC Filing on Google Icon
11/27/2019Millennium Management LLC41,978$0.14M0.0%N/A0.615%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
BioCardia logo
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Read More on BioCardia

Today's Range

Now: $2.02
Low: $1.92
High: $2.05

50 Day Range

MA: $1.76
Low: $1.36
High: $2.09

52 Week Range

Now: $2.02
Low: $1.10
High: $3.49

Volume

21,688 shs

Average Volume

719,085 shs

Market Capitalization

$35.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Who are the company insiders with the largest holdings of BioCardia?

BioCardia's top insider investors include:
  1. Peter Altman (CEO)
  2. Eric Duckers (Insider)
Learn More about top insider investors at BioCardia.

Who are the major institutional investors of BioCardia?

BioCardia's top institutional shareholders include:
  1. Millennium Management LLC — 0.16%
  2. Concourse Financial Group Securities Inc. — 0.00%
Learn More about top institutional investors of BioCardia stock.

Which institutional investors are buying BioCardia stock?

Within the last quarter, BCDA stock was bought by institutional investors including:
  1. Millennium Management LLC
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast
He predicted the 2020 crash a month before it happened…He predicted this year’s collapse back in January…

And now, he’s issuing a brand-new warning – along with a unique solution.
Details here.